Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α

Immunopharmacology

Volumn 36, Issue 1, 1997, Pages 9-15

  Shannon, E J ^a   Sandoval, Felipe ^a   Krahenbuhl, James L ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

hydrolyzed thalidomide; IL 2; thalidomide; TNF

Indexed keywords

INTERLEUKIN 2; LIPOPOLYSACCHARIDE; STAPHYLOCOCCUS ENTEROTOXIN A; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; DRUG HYDROLYSIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

BIOTRANSFORMATION; FEMALE; HUMANS; HYDROLYSIS; INTERLEUKIN-2; LEPROSTATIC AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; STIMULATION, CHEMICAL; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030897450     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(96)00154-3     Document Type: Article

References (21)

1. Barnhill RL, Doll NJ, Millikan LE, Hastings, RC. Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11: 814-819.
2. Faigle JW, Keberle H, Riess W, Schmie K. The metabolic fate of thalidomide. Experientia 1962; 18: 389.
3. Fernandez LP, Schlegel PG, Baker J, Chen Y, Chao NJ. Does thalidomide affect IL-2 response and production? Exp Hematol 1995; 23: 978-985.
4. Green JN, Benson BC. The spectrophotometric determination of thalidomide in body fluids. J Pharmacol 1961; 13: 117-121.
5. Günzler V, Hanauske-Abel HM, Tschank G, Schulte-Wissermann H. Immunological effects of thalidomide. Arzneim-Forsch/Drug Res 1986; 36(11): 1138-1141.
6. Hastings RC. Studies on the mechanism of action of thalidomide in inflammation. PhD Thesis 1971, Tulane Univ, New Orleans, LA.
7. Hastings RC. Kellersberger Memorial Lecture, 1979: Immunosuppressive/anti-inflammatory thalidomide analogues. Ethiop Med J 1980; 18: 65.
8. Hastings RC, Morales MJ, Shannon EJ. Studies on the mechanism of action of thalidomide in leprosy. Pharmacologist 1976; 18: 218.
9. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-167.
10. Miyachi Y, Ozaki M. Thalidomide does not affect polymorphonuclear leukocyte (PMN) chemotaxis. Jap J Lepr 1981; 50: 62-64.
11. Nielsen H, Valerius NH. Thalidomide enhances superoxide anion release from human polymorphonuclear and mononuclear leukocytes. Acta Path Microbiol Immunol Scand Sect C 1986; 94: 233-237.
12. Nishimura K, Hashimoto Y, Iwasaki S. Enhancement of phorbol ester-induced production of tumor necrosis factor α by thalidomide. Biomed Biophys Res Commun 1994; 199(2): 455-460.
13. Peterson PM, Hu S, Sheng WS, Kravitz FH, Molitor TW, Chatterjee D, Chao CC. Thalidomide inhibits tumor necrosis factor-α production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 1995; 172: 1137-1140.
14. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
15. Sasaki K, Shibata Y, Nishimura K, Hashimoto Y, Iwasaki S. Enhancement of 12-O-Tetradecanoylphorbol-13-Acetate-induced tumor necrosis factor alpha production by Phenethylphthalimide analogs. Biol Pharm Bull 1994; 17: 1313-1315.
16. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965; 25: 338-351.
17. Shannon EJ. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells. Immunopharmacol Immunotoxicol 1996; 18(1) (in press).
18. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 1995; 31: 109-116.
19. Shibata Y, Shichita M, Sasaki K, Nishimura K, Hashimoto Y, Iwasaki S. N-Alkylphthalimides structural requirement of thalidomidal action on 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor alpha production by human leukemia HL-60 cells. Chem Pharm Bull 1995; 43: 177-179.
20. Von Beckmann R, Kampf HH. Zur quantitiven Bestimmung und zum qualitativen Nachweis von N-Phthal-glutaminsäure-imid (Thalidomid). Arzneim-Forsch/Drug Res 1961; 11: 45-47.
21. Williams RT. Thalidomide, A study of Biochemical Teratology. Arch Environ Health 1968; 16: 493-502.